Literature DB >> 11855985

Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues.

Stephen Hindley1, Stephen A Ward, Richard C Storr, Natalie L Searle, Patrick G Bray, B Kevin Park, Jill Davies, Paul M O'Neill.   

Abstract

The potent antimalarial activity of chloroquine against chloroquine-sensitive strains can be attributed, in part, to its high accumulation in the acidic environment of the heme-rich parasite food vacuole. A key component of this intraparasitic chloroquine accumulation mechanism is a weak base "ion-trapping" effect whereupon the basic drug is concentrated in the acidic food vacuole in its membrane-impermeable diprotonated form. By the incorporation of amino functionality into target artemisinin analogues, we hoped to prepare a new series of analogues that, by virtue of increased accumulation into the ferrous-rich vacuole, would display enhanced antimalarial potency. The initial part of the project focused on the preparation of piperazine-linked analogues (series 1 (7-16)). Antimalarial evaluation of these derivatives demonstrated potent activity versus both chloroquine-sensitive and chloroquine-resistant parasites. On the basis of these observations, we then set about preparing a series of C-10 carba-linked amino derivatives. Optimization of the key synthetic step using a newly developed coupling protocol provided a key intermediate, allyldeoxoartemisinin (17) in 90% yield. Further elaboration, in three steps, provided nine target C-10 carba analogues (series 2 (21-29)) in good overall yields. Antimalarial assessment demonstrated that these compounds were 4-fold more potent than artemisinin and about twice as active as artemether in vitro versus chloroquine-resistant parasites. On the basis of the products obtained from biomimetic Fe(II) degradation of the C-10 carba analogue (23), we propose that these analogues may have a mode of action subtly different from that of the parent drug artemisinin (series 1 (7-16)) and other C-10 ether derivatives such as artemether. Preliminary in vivo testing by the WHO demonstrated that four of these compounds are active orally at doses of less than 10 mg/kg. Since these analogues are available as water-soluble salts and cannot form dihydroartemisinin by P450-catalyzed oxidation, they represent useful leads that might prove to be superior to the currently used derivatives, artemether and artesunate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855985     DOI: 10.1021/jm0109816

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy.

Authors:  Rita Capela; Ghislain G Cabal; Philip J Rosenthal; Jiri Gut; Maria M Mota; Rui Moreira; Francisca Lopes; Miguel Prudêncio
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

2.  Functionalisation of artemisinin and its ring-contracted derivatives.

Authors:  Tine Van Neck; Sarah Van Mierloo; Wim Dehaen
Journal:  Molecules       Date:  2007-03-09       Impact factor: 4.411

3.  Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology.

Authors:  Maria del Pilar Crespo; Thomas D Avery; Eric Hanssen; Emma Fox; Tony V Robinson; Peter Valente; Dennis K Taylor; Leann Tilley
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

4.  A mitochondria-targeting artemisinin derivative with sharply increased antitumor but depressed anti-yeast and anti-malaria activities.

Authors:  Chen Sun; Yu Cao; Pan Zhu; Bing Zhou
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

Review 5.  Prodrugs for the treatment of neglected diseases.

Authors:  Man Chin Chung; Elizabeth Igne Ferreira; Jean Leandro Santos; Jeanine Giarolla; Daniela Gonçales Rando; Adélia Emília Almeida; Priscila Longhin Bosquesi; Renato Farina Menegon; Lorena Blau
Journal:  Molecules       Date:  2007-03-19       Impact factor: 4.411

6.  pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members.

Authors:  Yitong J Zhang; Byron Gallis; Michio Taya; Shusheng Wang; Rodney J Y Ho; Tomikazu Sasaki
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

7.  N-alkyl triphenylvinylpyridinium conjugated dihydroartemisinin perturbs mitochondrial functions resulting in enhanced cancer versus normal cell toxicity.

Authors:  Mahboubeh Varmazyad; Mira M Modi; Amanda L Kalen; Ehab H Sarsour; Brett Wagner; Juan Du; Michael K Schultz; Garry R Buettner; F Christopher Pigge; Prabhat C Goswami
Journal:  Free Radic Biol Med       Date:  2021-02-06       Impact factor: 8.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.